IDSA News - February 2012  (Plain Text Version)

Return to Graphical Version

 

In this issue:
Patient Care and Science
•  CDC Guidance for Influenza Antivirals Remains Unchanged
•  Medicare Website Reports Hospital CLABSI Rates
•  ACIP Recommends Tdap for All Adults, Including Those 65 and Older
•  Drug Approvals, Recalls, Adverse Events Update
Clinical Practice Management
•  Medicare Physician Payment Cuts Delayed for 10 Months
Global ID
•  Interview Series: CDC’s Role in Global HIV and TB
•  Experts Highlight Role of Prevention Interventions in Global AIDS Fight
•  PEPFAR Takes Hit in Obama’s FY2013 Budget
Policy and Advocacy
•  Obama’s FY2013 Budget Mixed Bag for ID, HIV/AIDS
•  HHS Advisory Group Recommends Voluntary Measures to Boost HCW Influenza Vaccination
Your Colleagues
•  Check Out “My IDSA” for Latest Member News
Education & Resources
•  CDC Lyme Disease Webinar: CME Credit Available
•  Adolescent Vaccination Education Materials Available
Top Stories
•  From the President:
How Is Antimicrobial Resistance Affecting Your Patients?

•  IDSA Urges Congress, FDA to Boost Antibiotic R&D
•  IDWeek 2012 Now Accepting Abstract Submissions
•  IDSA Journal Club

 

CDC Guidance for Influenza Antivirals Remains Unchanged

A recent review of randomized clinical trial data for influenza neuraminidase inhibitor antiviral medications published by the Cochrane Collaboration, and two related commentaries published in the British Medical Journal (available here and here), have raised questions about the value of antiviral medications for the prevention and treatment of influenza. After reviewing the available evidence, the Centers for Disease Control and Prevention (CDC) continues to recommend the use of the neuraminidase inhibitor antiviral drugs (oral oseltamivir and inhaled zanamivir) as an important adjunct in influenza prevention and treatment. Read CDC’s online statement for more information.

A meta-analysis review of observational studies of influenza antiviral treatment was published this week in the Annals of Internal Medicine. Analyses focus on hospitalized patients and pregnant women, where there are no good randomized trial data, and provide strong support for CDC and IDSA recommendations to treat high-risk patients and to begin therapy early.